Patients currently taking metformin will be eligible
Patients may not be taking metformin for a reason other than study participation
Patients must not receive metformin for at least 5 days prior to enrollment and for the duration of study treatment
Subjects may have diabetes mellitus but must not be taking metformin
Known hypersensitivity or intolerance to metformin
Known hypersensitivity to metformin
Subjects currently treated with metformin and/or bicalutamide or who have been treated with metformin and/or bicalutamide in the past 6 months
Prior or current use of metformin within the past 3 months
History of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effects
Subjects may have diabetes mellitus but must not be taking metformin or have previously taken metformin within previous year
Known hypersensitivity or intolerance to metformin
Subjects who are pregnant or breastfeeding, or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding 4 weeks
Diabetic subjects that are managed by taking metformin or insulin
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered:\r\n* Class D:\r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
Both arms: patients should not have received metformin within 6 months prior to registration\r\n* Arm B: patients who were on metformin while on PD-1/PD-L1 inhibitors are not eligible
Patients must not have any of the following contraindications to metformin:\r\n* Hypersensitivity to metformin or any component of the formulation\r\n* Kidney dysfunction or abnormal creatinine (Cr < 2 ng/mL) from any cause\r\n* Acute or metabolic acidosis
Patients must be at least 5 half-lives beyond previous treatment with metformin and currently not taking metformin
History of hypersensitivity to TAK-228 or metformin
Subjects who are pregnant or breastfeeding or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered\r\n* Class D \r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
Known sulfonylurea treatment within 7 days prior to registration; sulfonylureas include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin); nateglinide (Starlix); glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase); and glibornuride (Glutril)
Patients who are currently taking metformin; prior metformin use is allowed if last dose was 3 months previous to this trial
Currently taking metformin, sulfonyureas, thiazolidenediones or insulin for any reason
History of hypersensitivity to temsirolimus or metformin
Subjects with known diabetes and those taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Patients taking metformin or digoxin
Patients currently using metformin (metformin hydrochloride), other oral hypoglycemic agents or insulin
Patients must NOT be taking metformin or have been on metformin in the past 6 months
Diabetic patients who are on metformin are eligible as long as they have been on metformin for less than 6 months (estimated 6 months or less duration of metformin therapy from start of metformin to enrollment on study)
Current use of metformin for more than 6 months prior to enrollment on study
Patients who received aspirin or metformin within the past 28 days
Patients taking medications with known interactions with metformin or aspirin
Currently taking metformin, sulfonylureas, thiazolidinediones, or insulin for any reason
Have no contraindications to short-term metformin therapy
Need to be able to undergo metformin treatment for a duration of 12 weeks (+/- 7 days) prior to repeat endometrial biopsy
Are currently taking metformin or have taken metformin in the past 6 months or have a history of an allergic reaction or intolerance at any time to metformin
Are taking a drug that may significantly interact or influence the metabolism of metformin
Prior metformin treatment OR EGFR targeted therapy
Patients taking Metformin for any reason within 30 days of enrollment to the study
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
Currently taking metformin, sulfonylureas, thiazolidinedione, insulin, or other antidiabetic drugs for any reason
Known hypersensitivity or intolerance to metformin
Patients already receiving metformin or anti-diabetic medications are INELIGIBLE
Metformin use in the last 6 months
A known hypersensitivity to metformin
Known intolerance to doxorubicin, metformin, or vincristine
Patients who have a need to continue hydroxyurea while on study\r\n* Please note: patients may continue on hydroxyurea only until the first dose of metformin is to be given
Known hypersensitivity to metformin or statins
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
All medications other than those that may cause myelosuppression are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Current metformin therapy
Subjects who are pregnant or may become pregnant during metformin administration; pregnancy testing will be done in conjunction with preradiation protocols
Subjects on metformin for any reason during the preceding 4 weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
All medications are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Known hypersensitivity or intolerance to metformin
Patients currently receiving or scheduled to receive a chemotherapy infusion other than adriamycin/cyclophosphamide prior to initiation of the metformin adaptation phase are not eligible; patients who are receiving adriamycin/cyclophosphamide must be scheduled to be at least 8 days post-chemotherapy infusion prior to initiation of the metformin adaptation phase in order to be eligible
Patients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)
Contraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metformin
Women who have taken metformin within the past 90 days
Current use of any drug (except metformin) or anticipated change in concomitant medication, which the investigatorâ€™s opinion could interfere with the glucose metabolism (e.g. systemic corticosteroids).
Currently taking medication that may impact weight (e.g., Synthroid, metformin)
Current or prior regular use of metformin within the past 3 months
Current use of metformin or other anti-diabetic agents, or hypersensitivity or allergy to metformin
VITAMIN D/METFORMIN SUBARM OF LOW GRADE DYSPLASIA/NO DYSPLASIA ARM:
VITAMIN D/METFORMIN SUBARM OF THE DYSPLASIA/NO DYSPLASIA ARM:
Participants may not be using metformin, cimetidine (Tagamet), furosemide (Lasix), nifedipine (Cardizem), or any other drug contraindicated for use with metformin
No known hypersensitivity or intolerance to metformin
No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Prior treatment with metformin
Known allergy to metformin or other biguanide (Proguanil)
Participants who are taking metformin at the time of the exam are excluded
Taking metformin (example: Glucophage, Glucovance, Avandamet, Metaglip)
Currently taking Glucophage or Glucovance (metformin)
NORMAL VOLUNTEERS: Be taking metformin, aminoglycosides, other nephrotoxic medications, or daily use of NSAIDs
Patients with type 2 diabetes mellitus (T2DM) being treated with metformin (any dose) for a clinical indication at the time of study enrollment are eligible, and will continue metformin treatment as clinically indicated during the presurgical study period. Their dose of metformin will NOT be changed
Patients not on metformin at the time of study entry must be willing to take metformin extended release (Glucophage XR, 750 mg QD for 4 days, then 750 mg BID for 3-6 days) for a total of 7-10 days prior to surgery\r\n* Patients do not require a diagnosis of diabetes to be enrolled in the study
All patients must be willing to keep a drug diary indicating the dates and times of metformin administration
History of diabetes that is currently being treated without metformin
Patients who, at the time of study entry, are not taking metformin for a clinical indication, and who will need a radiographic analysis with an iodinated contrast agent during the metformin study treatment period
This criterion does not apply to patients taking clinically indicated metformin at the time of study entry
Known hypersensitivity to metformin
Must have been off metformin for at least 2 weeks prior to starting IFN gamma
Participants who are already on treatment with metformin, except when metformin can be held for 4 weeks prior to the start of the study
Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas
